DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual ...

Teva Pharmaceutical Industries and partner Alvotech said the Food and Drug Administration agreed to review their AVTO6 ...

The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for ...

Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...

Alvotech and Teva Pharmaceuticals said on Tuesday that the U.S. FDA has accepted for review a Biologics License Application ...

The increasing prevalence of chronic conditions like cardiovascular disease is driving the demand for transmucosal drugs. Key factors contributing to the transmucosal drugs market's growth from ...

Calgary Health Foundation is proud to announce the opening of Rockyview General Hospital's expanded endoscopy unit. The new Florence and Lloyd Cooper Endoscopy Unit was made possible thanks to $10M in ...

Are you getting enough of the 'good fats' your body needs to stay healthy? Probably not! EPA and DHA omega-3s, nutrients found naturally in fatty fish and marine microalgae, are important for every ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval for its biosimilar to be completed in the fourth quarter of 2025.